347 related articles for article (PubMed ID: 31060319)
21. Proton pump inhibitors, osteoporosis, and osteoporosis-related fractures.
Fournier MR; Targownik LE; Leslie WD
Maturitas; 2009 Sep; 64(1):9-13. PubMed ID: 19674854
[TBL] [Abstract][Full Text] [Related]
22. Use of proton pump inhibitors and risk of osteoporosis-related fractures.
Targownik LE; Lix LM; Metge CJ; Prior HJ; Leung S; Leslie WD
CMAJ; 2008 Aug; 179(4):319-26. PubMed ID: 18695179
[TBL] [Abstract][Full Text] [Related]
23. Proton pump inhibitor use and risk of hip fracture in patients with type 2 diabetes.
Chou YS; Jiang HJ; Chen CH; Ho PS; Lee TC
Sci Rep; 2020 Aug; 10(1):14081. PubMed ID: 32826941
[TBL] [Abstract][Full Text] [Related]
24. Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
Chiu HF; Huang YW; Chang CC; Yang CY
Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1131-6. PubMed ID: 20872906
[TBL] [Abstract][Full Text] [Related]
25. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
26. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
Targownik LE; Lix LM; Leung S; Leslie WD
Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
[TBL] [Abstract][Full Text] [Related]
27. The relationship between long-term proton pump inhibitor therapy and skeletal frailty.
Lau AN; Tomizza M; Wong-Pack M; Papaioannou A; Adachi JD
Endocrine; 2015 Aug; 49(3):606-10. PubMed ID: 25948072
[TBL] [Abstract][Full Text] [Related]
28. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.
Ngamruengphong S; Leontiadis GI; Radhi S; Dentino A; Nugent K
Am J Gastroenterol; 2011 Jul; 106(7):1209-18; quiz 1219. PubMed ID: 21483462
[TBL] [Abstract][Full Text] [Related]
29. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
Lau YT; Ahmed NN
Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
[TBL] [Abstract][Full Text] [Related]
30. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
[TBL] [Abstract][Full Text] [Related]
31. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
[TBL] [Abstract][Full Text] [Related]
32. The association between proton pump inhibitors and hyperparathyroidism: a potential mechanism for increased fracture-results of a large observational cohort study.
Fitzpatrick D; Lannon R; Laird E; Ward M; Hoey L; Hughes CF; Strain JJ; Cunningham C; McNulty H; Molloy AM; McCarroll K
Osteoporos Int; 2023 Nov; 34(11):1917-1926. PubMed ID: 37530847
[TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitor use and the antifracture efficacy of alendronate.
Abrahamsen B; Eiken P; Eastell R
Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
[TBL] [Abstract][Full Text] [Related]
34. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
Adams AL; Black MH; Zhang JL; Shi JM; Jacobsen SJ
Ann Epidemiol; 2014 Apr; 24(4):286-90. PubMed ID: 24507954
[TBL] [Abstract][Full Text] [Related]
35. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA
Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193
[TBL] [Abstract][Full Text] [Related]
36. Long-term use of proton pump inhibitors adversely affects minerals and vitamin metabolism, bone turnover, bone mass, and bone strength.
Hussain MS; Mazumder T
J Basic Clin Physiol Pharmacol; 2022 Sep; 33(5):567-579. PubMed ID: 34687598
[TBL] [Abstract][Full Text] [Related]
37. Proton pump inhibitors and bone fractures?
Laine L
Am J Gastroenterol; 2009 Mar; 104 Suppl 2():S21-6. PubMed ID: 19262543
[TBL] [Abstract][Full Text] [Related]
38. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA; Jick H
Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
[TBL] [Abstract][Full Text] [Related]
39. Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.
Vangala C; Niu J; Lenihan CR; Mitch WE; Navaneethan SD; Winkelmayer WC
Clin J Am Soc Nephrol; 2018 Oct; 13(10):1534-1541. PubMed ID: 30262672
[TBL] [Abstract][Full Text] [Related]
40. Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Fusaro M; D'Arrigo G; Pitino A; Iervasi G; Tentori F; Robinson B; Aghi A; Bieber B; Mccullogh K; Fabris F; Plebani M; Giannini S; Gallieni M; Tripepi G
J Bone Miner Res; 2019 Dec; 34(12):2238-2245. PubMed ID: 31365145
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
